Klertis (Sunitinib)

Sunitinib blocks several receptor tyrosine kinases such as VEGFR, PDGFR, KIT and FLT3. By inhibiting these receptors it reduces angiogenesis, limits cell proliferation, and promotes cancer‑cell apoptosis, thereby slowing tumor development.

The dosage of Klertis is individualized by the treating physician based on the patient’s condition, weight, renal function and tolerability. Only a qualified prescriber can determine the appropriate dosing schedule.

Safety data for sunitinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and while breastfeeding unless the potential benefit justifies the potential risk to the infant. Consultation with a healthcare professional is essential.

To request Klertis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Klertis (sunitinib) targets a broader spectrum of kinases, including VEGFR, PDGFR, KIT and FLT3, whereas some alternatives focus on a narrower set. This broader inhibition can offer efficacy in multiple tumor types but may also be associated with a distinct safety profile that requires careful monitoring.

Klertis should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency.

Klertis is taken orally, usually as a whole tablet swallowed with water. The exact timing (e.g., with or without food) and dosing interval are determined by the prescribing clinician based on the therapeutic plan.

Serious risks include cardiac dysfunction, severe hypertension, hepatic toxicity, and thromboembolic events. Patients should be monitored regularly for signs of heart failure, liver enzyme elevations, blood‑pressure spikes and clotting complications.

Klertis is contraindicated in patients with known hypersensitivity to sunitinib or any of its excipients, and in those with uncontrolled hypertension or severe hepatic impairment. Caution is also advised for individuals taking strong CYP3A4 inhibitors or inducers.